CA3093295A1 - Serine protease inhibitor kazal (spik) compositions and methods - Google Patents

Serine protease inhibitor kazal (spik) compositions and methods Download PDF

Info

Publication number
CA3093295A1
CA3093295A1 CA3093295A CA3093295A CA3093295A1 CA 3093295 A1 CA3093295 A1 CA 3093295A1 CA 3093295 A CA3093295 A CA 3093295A CA 3093295 A CA3093295 A CA 3093295A CA 3093295 A1 CA3093295 A1 CA 3093295A1
Authority
CA
Canada
Prior art keywords
seq
spik
sequence
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3093295A
Other languages
English (en)
French (fr)
Inventor
Xuanyong Lu
Felix LU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imcare Biotech LLC
Original Assignee
Imcare Biotech LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imcare Biotech LLC filed Critical Imcare Biotech LLC
Publication of CA3093295A1 publication Critical patent/CA3093295A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3093295A 2018-03-06 2019-03-06 Serine protease inhibitor kazal (spik) compositions and methods Pending CA3093295A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862639345P 2018-03-06 2018-03-06
US62/639,345 2018-03-06
US201862639850P 2018-03-07 2018-03-07
US62/639,850 2018-03-07
PCT/US2019/020999 WO2019173503A2 (en) 2018-03-06 2019-03-06 Serine protease inhibitor kazal (spik) compositions and methods

Publications (1)

Publication Number Publication Date
CA3093295A1 true CA3093295A1 (en) 2019-09-12

Family

ID=65818672

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3093295A Pending CA3093295A1 (en) 2018-03-06 2019-03-06 Serine protease inhibitor kazal (spik) compositions and methods

Country Status (6)

Country Link
US (2) US12180301B2 (cg-RX-API-DMAC7.html)
EP (1) EP3762426A2 (cg-RX-API-DMAC7.html)
JP (2) JP7328261B2 (cg-RX-API-DMAC7.html)
CN (2) CN120005029A (cg-RX-API-DMAC7.html)
CA (1) CA3093295A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019173503A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120005029A (zh) 2018-03-06 2025-05-16 英凯尔生物科技有限责任公司 丝氨酸蛋白酶抑制剂Kazal(SPIK)组合物和方法
JP7658946B2 (ja) * 2019-07-08 2025-04-08 インケア バイオテック, エルエルシー カザール型抗セリンプロテアーゼ阻害因子(spik)抗体、免疫複合体、及び使用方法
KR20220080098A (ko) 2019-09-11 2022-06-14 아임케어 바이오테크, 엘엘씨. 항-세린 프로테아제 억제제 카잘(spik) 항체의 에피토프
EP4211468A4 (en) 2020-09-11 2024-10-09 Glympse Bio, Inc. DETECTION OF EX VIVO PROTEASE ACTIVITY FOR DETECTION/DIAGNOSTIC, STAGING, MONITORING AND TREATMENT OF DISEASES

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
EP0731106B1 (en) 1993-10-01 2004-11-17 Teikoku Hormone Mfg. Co., Ltd. Dolastatin derivatives
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6248564B1 (en) 1997-08-29 2001-06-19 Harvard University Mutant MHC class I molecules
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20050123536A1 (en) 2001-11-20 2005-06-09 Che-Leung Law Treatment of immunological disorders using anti-dc30 antibodies
CA2494104A1 (en) 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
US8193328B2 (en) 2005-09-08 2012-06-05 Philadelphia Health & Education Corporation Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents
CN101970498A (zh) 2007-10-25 2011-02-09 维文蒂阿生物技术公司 针对变体HnRNPG的癌相关表位的抗体及其应用
PE20120877A1 (es) 2009-04-01 2012-08-06 Genentech Inc ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
US20110206697A1 (en) 2010-02-19 2011-08-25 The Regents Of The University Of Michigan Spink1 targeted therapy
US20140308657A1 (en) * 2010-12-09 2014-10-16 Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine Serine protease inhibitor kazal antibodies
US9206257B2 (en) 2011-04-19 2015-12-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
CN104994875B (zh) 2013-02-15 2018-10-09 免疫医疗公司 嵌合和人源化抗组蛋白抗体
US10746742B2 (en) 2014-04-25 2020-08-18 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
AU2017239637A1 (en) 2016-03-29 2018-11-15 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
EP4219559A3 (en) * 2017-12-22 2023-10-18 Jounce Therapeutics, Inc. Antibodies for lilrb2
CN120005029A (zh) 2018-03-06 2025-05-16 英凯尔生物科技有限责任公司 丝氨酸蛋白酶抑制剂Kazal(SPIK)组合物和方法
CN109678950B (zh) 2019-01-08 2022-05-10 灏灵赛奥(天津)生物科技有限公司 spink1抗原、能够特异性结合spink1的抗体及其功能片段及其应用和产品
CN109776679B (zh) * 2019-01-08 2022-06-17 灏灵赛奥(天津)生物科技有限公司 一种丝氨酸蛋白酶抑制因子spink1的抗体、其制备方法和应用
JP7658946B2 (ja) 2019-07-08 2025-04-08 インケア バイオテック, エルエルシー カザール型抗セリンプロテアーゼ阻害因子(spik)抗体、免疫複合体、及び使用方法

Also Published As

Publication number Publication date
CN120005029A (zh) 2025-05-16
US20210253734A1 (en) 2021-08-19
EP3762426A2 (en) 2021-01-13
JP2021515597A (ja) 2021-06-24
CN112292401A (zh) 2021-01-29
JP7539536B2 (ja) 2024-08-23
JP2023166377A (ja) 2023-11-21
WO2019173503A2 (en) 2019-09-12
JP7328261B2 (ja) 2023-08-16
US20250353927A1 (en) 2025-11-20
US12180301B2 (en) 2024-12-31
WO2019173503A3 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
US20250353927A1 (en) Serine protease inhibitor kazal (spik) compositions and methods
JP6180931B2 (ja) 癌の診断および/または予後のための新規な抗体
US12377162B2 (en) Anti-serine protease inhibitor kazal (SPIK) antibodies, immunoconjugates, and methods of use
AU2017204683B2 (en) Compositions and methods for assessing the risk of cancer occurrence
EP2765140A2 (en) Cadherin-2 or Mucin-13 binding molecules for cancer treatment
JP6977105B2 (ja) Igf−1r抗体および癌の診断のためのその使用
JP2026012693A (ja) 抗セリンプロテアーゼインヒビターkazal(spik)抗体のエピトープ
US20140271477A1 (en) Monoclonal antibodies to egfr, and uses therefor
JP2018516876A (ja) Igf−1r抗体および癌の診断のためのその使用
CA3009768C (en) Compositions and methods for assessing the risk of cancer occurrence
TW202521156A (zh) 重組抗體、包含其之套組以及其於診斷癌症之用途
HK1262633B (en) Compositions and methods for assessing the risk of cancer occurrence

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220921

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250228

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250228

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250228

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250512

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250908